PersonalRX places the patient at the center of the pharmacy care model. We are a home delivery pharmacy providing VIP services and packaging to improve patient compliance — with no added costs. Our pharmacists are available 24/7, and each patient has the direct phone number of their dedicated pharmacy technician. 

Min investment
Days Left
East Rutherford, NJ

CrowdLustro Research Report

Security Type
A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.
October 28, 2020
June 01, 2021
Valuation Cap

Use of Proceeds


  • 7.5% will be used for fundraising fees at WeFunder
  • 92.5% will be used for marketing and general overhead.


  • We expect 30% of the proceeds of the offering to be used for marketing our services, including to new patients through various marketing channels including Direct To Consumer Campaigns (DTC)
  • 38% is expected to be used for operating expenses including, without limitation, customer support costs, rent, utilities, technology, and other operational costs
  • 12.5% is expected to be used for purchases of inventory
  • 12% is expected to be used for interest expense and short-term debt repayment
  • 7.5% for Wefunder campaign costs.

Actual allocations of proceeds may vary from these estimates in the Company's discretion


Lawrence Margolis
Larry is a former Wall Street Broker and investor specializing in the health and technology marketplaces. His experience in financial markets includes positions at The Bear Stearns Companies and Prudential Securities.

Charles Oestreicher President and Chief Operating Officer
Charlie, an industry veteran, brings to PersonalRX nearly 30 years of leadership and operations experience. He has worked for several leading Pharmacy Benefit Managers (CVS Health, Express Scripts, Medco Health Services) in various executive roles.

Vaibhav Kullar Chief Technology Officer
Vaibhav is an award-winning technology developer and entrepreneur. He’s pioneered development of the RX2 Mobile and Internal systems. He has held senior and executive risk management and analytics roles at Barclays Investment Bank and Credit Suisse.

Gillian Giannone, PharmD, R. Ph. Director of Pharmacy Operations
Gillian brings 10 years of pharmacy experience in a variety of settings to her leadership role. Earlier in her career, Gillian was a clinical pharmacist at one of the largest pharmacy benefit management companies in the US.

Dana Stripling Director of Training and Patient Experience
Dana is an accomplished certified trainer focused on consistently improving the patient experience. Prior to PersonalRX, she served as an EPIC Software Credentialed trainer at Englewood Hospital and Medical Center.

Cheryl Fine Controller and Director of Talent
Cheryl is a financial services professional with more than 20 years experience. She has been a Certified Quickbooks Online Accountant since 2016 and is a Platinum Pro Advisor. Her prior finance positions were in medical billing, printing and retail.

Gregg Kattine Advisor - Healthcare Relationships
Gregg offers PersonalRX guidance gleaned from 40 plus years as a successful investor and business operator. His health-related investments include a medical claims and insurance billing company that he cofounded in 1993 and sold for a profit in 2015

Research Reports

No reports have been submitted

Become a Reporter

Key Deal Facts

We've shipped 10 million Square Packs (dose packs) and generated revenue in excess of $26 million!
The pharmacy market is $500 billion annually. So we have plenty of room to grow.
We focus on the 41 million Americans who take 5 or more medications.
Our proprietary RX2 Mobile app and monthly "Care Calls" help us "surround the patient with care."
We are licensed and delivering patient medications in 38 states.
Our mission is to "Improve Lives" and patient healthcare through increased patient compliance.
Recent acquisitions in this market have totaled as high as $1 billion.
Relationship with Fortune 500 company.